Ku Affects The Ataxia And Rad 3-Related/Chk1-Dependent S Phase Checkpoint Response After Camptothecin Treatment

Hongyan Wang,Xiang Wang,Xiang-Yang Zhou,David J Chen,Gloria C Li,George Iliakis,Ya Wang
IF: 11.2
2002-01-01
Cancer Research
Abstract:Camptothecin (CPT) that targets DNA topoisomerase I is one of the most promising broad-spectrum anticancer drugs in development today. The cytotoxicity of CPT is S phase (S)-specific because the collision of advancing replication forks with CPT-topoisomerase I-DNA complexes results in DNA damage. After DNA damage, proliferating cells could actively slow down the DNA replication through an S checkpoint to provide time for repair. We report now that there is an activated S checkpoint response in CPT-treated mammalian cells. This response is regulated by Ataxia and Rad3-related (ATR)/CHK1 pathway. Compared with their wild-type counterparts, CPT-treated Ku80(-/-) cells showed stronger inhibition of DNA replication. This stronger inhibition had no relationship with DNA-dependent protein kinase (DNA-PK) activity but correlated with the higher activities of ATR and the higher activities of CHK1 in such cells. Not only caffeine, the nonspecific inhibitor of ATR, or UCN-01, the nonspecific inhibitor of CHK1, but also the specific CHK1 antisense oligonucleotide abolished the stronger inhibition of DNA replication in CPT-treated Ku80(-/-) cells. These results in aggregate indicated that the stronger S checkpoint in CPT-treated Ku80(-/-) cells is regulated through the highly activated ATR/CHK1 pathway.
What problem does this paper attempt to address?